...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Antiretroviral Drug Exposures Reported to Texas Poison Centers
【24h】

Antiretroviral Drug Exposures Reported to Texas Poison Centers

机译：向德克萨斯毒物中心报告了抗逆转录病毒药物暴露

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. A number of different antiretrovira! drugs are used to manage patients with human immunodeficiency virus (HIV). Objective. This study describes antiretroviral drug exposures reported to a large statewide poison center system. Methods. Cases were all antiretroviral drug exposures reported to the Texas Poison Center Network during 2000 to 2014. The distribution of cases was determined for various demographic and clinical factors. Results. Of a total of 632 exposures, the most commonly reported drugs were emtricitabine-tenofovir combination (17.1%), efavirenz-emtricitabine-tenofovir combination (1 3.8%), ritonavir (10.9%), lamivudine-zidovudine combination (10.3%), and efavirenz (10.1%). The annual number of antiretroviral drug exposures increased from 34 in 2000 to 67 in 2014. Males comprised 67.9% of the patients; 72.2% were 20 years or older. The exposures were 58.5% unintentional and 37.5% intentional. Only antiretroviral drugs were reported in 440 of the exposures. Of these exposures, 62.5% were managed on site, 28.0% were already at or en route to a health care facility when the poison center was contacted, and 8.6% were referred to a health care facility. The exposures were not serious in 88.7% of these cases. The most frequently reported adverse clinical effects were vomiting (5.7%), nausea (4.8%), dizziness/vertigo (3.2%), and drowsiness/lethargy (3.2%). Conclusions. The most commonly reported antiretroviral drugs were emtricitabine-tenofovir combination and efavirenz-emtricitabine-tenofovir combination. The patients were most likely to be adults and males. The exposures tended to be unintentional. Of those exposures involving only antiretroviral drugs, the majority of the exposures were not serious and could be managed outside of a health care facility.
机译：背景。许多不同的antiretrovira！药物用于治疗人类免疫缺陷病毒（HIV）患者。目的。这项研究描述了报告给全州大型毒物中心系统的抗逆转录病毒药物暴露。方法。病例均为2000年至2014年间向德克萨斯州毒物中心网络报告的抗逆转录病毒药物暴露。确定了各种人口统计学和临床​​因素的病例分布。结果。在632次接触中，最常报告的药物是恩曲他滨-替诺福韦联合（17.1％），依非韦伦-恩曲他滨-替诺福韦联合（1 3.8％），利托那韦（10.9％），拉米夫定-齐多夫定联合（10.3％）和依法韦仑（10.1％）。每年的抗逆转录病毒药物暴露次数从2000年的34次增加到2014年的67次。男性占患者的67.9％; 20岁或以上的比例为72.2％。意外暴露为58.5％，故意暴露为37.5％。 440次接触中仅报道了抗逆转录病毒药物。在这些暴露中，有62.5％是在现场管理的，有28.0％的人在与毒物中心联系时已经在或途中到达医疗机构，还有8.6％的病人被转介到医疗机构。在这些病例中，接触率不严重，占88.7％。最常见的不良临床反应是呕吐（5.7％），恶心（4.8％），头晕/眩晕（3.2％）和嗜睡/嗜睡（3.2％）。结论。最常用的抗逆转录病毒药物是恩曲他滨-替诺福韦联合用药和依非韦伦-恩曲他滨-替诺福韦联合用药。患者最有可能是成年人和男性。暴露往往是无意的。在仅涉及抗逆转录病毒药物的暴露中，大多数暴露并不严重，可以在医疗机构之外进行管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号